BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37449494)

  • 1. Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain‑of‑function and targeting therapy (Review).
    Li M; Sun D; Song N; Chen X; Zhang X; Zheng W; Yu Y; Han C
    Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37449494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAMPT Inhibitor and P73 Activator Represses P53 R175H Mutated HNSCC Cell Proliferation in a Synergistic Manner.
    Cai BH; Bai ZY; Lien CF; Yu SJ; Lu RY; Wu MH; Wu WC; Chen CC; Hsu YC
    Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex.
    Verduci L; Ferraiuolo M; Sacconi A; Ganci F; Vitale J; Colombo T; Paci P; Strano S; Macino G; Rajewsky N; Blandino G
    Genome Biol; 2017 Dec; 18(1):237. PubMed ID: 29262850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
    Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
    Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
    Zhou G; Liu Z; Myers JN
    J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    García-Carracedo D; Cai Y; Qiu W; Saeki K; Friedman RA; Lee A; Li Y; Goldberg EM; Stratikopoulos EE; Parsons R; Lu C; Efstratiadis A; Philipone EM; Yoon AJ; Su GH
    Mol Cancer Res; 2020 Jun; 18(6):822-834. PubMed ID: 32152233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53-based therapeutics for head and neck squamous cell carcinoma.
    Tassone P; Old M; Teknos TN; Pan Q
    Oral Oncol; 2013 Aug; 49(8):733-7. PubMed ID: 23623836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population.
    Maruyama H; Yasui T; Ishikawa-Fujiwara T; Morii E; Yamamoto Y; Yoshii T; Takenaka Y; Nakahara S; Todo T; Hongyo T; Inohara H
    Cancer Sci; 2014 Apr; 105(4):409-17. PubMed ID: 24521534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
    Ge H; Yao Y; Jiang Y; Wu X; Wang Y
    Oral Dis; 2022 Apr; 28(3):611-620. PubMed ID: 33503275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk
    Tanaka N; Patel AA; Tang L; Silver NL; Lindemann A; Takahashi H; Jaksik R; Rao X; Kalu NN; Chen TC; Wang J; Frederick MJ; Johnson F; Gleber-Netto FO; Fu S; Kimmel M; Wang J; Hittelman WN; Pickering CR; Myers JN; Osman AA
    Clin Cancer Res; 2017 Nov; 23(21):6541-6554. PubMed ID: 28790110
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers.
    Kropveld A; Rozemuller EH; Leppers FG; Scheidel KC; de Weger RA; Koole R; Hordijk GJ; Slootweg PJ; Tilanus MG
    Lab Invest; 1999 Mar; 79(3):347-53. PubMed ID: 10092071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer.
    Coaxum SD; Tiedeken J; Garrett-Mayer E; Myers J; Rosenzweig SA; Neskey DM
    Oncotarget; 2017 Apr; 8(14):22991-23007. PubMed ID: 28160562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.
    Di Agostino S; Valenti F; Sacconi A; Fontemaggi G; Pallocca M; Pulito C; Ganci F; Muti P; Strano S; Blandino G
    Theranostics; 2018; 8(7):1850-1868. PubMed ID: 29556360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
    Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
    Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.